|
INCREASED RISK OF HYPERKALEMIA
|
CO-ADMINISTRATION MAY INCREASE C MAX & AUC LEVELS OF ALISKIREN BY ABOUT 50%
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CO-ADMINISTRATION MAY INCREASE C MAX & AUC LEVELS OF ALISKIREN BY ABOUT 50%
|
INCREASED RISK OF HYPERKALEMIA
|
INCREASED RISK OF HYPERKALEMIA
|
ALISKIREN PLASMA CONCENTRATION IS REDUCED UP TO 50%
|
CO-ADMINISTRATION MAY INCREASE C MAX & AUC LEVELS OF ALISKIREN BY ABOUT 50%
|
CO-ADMINISTRATION MAY INCREASE C MAX & AUC LEVELS OF ALISKIREN BY ABOUT 50%
|
ALISKIREN PLASMA CONCENTRATION IS REDUCED UP TO 50%
|
ALISKIREN PLASMA CONCENTRATION IS REDUCED UP TO 50%
|
INCREASED RISK OF HYPERKALEMIA
|
ALISKIREN PLASMA CONCENTRATION IS REDUCED UP TO 50%
|
INCREASED RISK OF HYPERKALEMIA
|
INCREASED RISK OF HYPERKALEMIA
|
INCREASED RISK OF HYPERKALEMIA
|
ALISKIREN REDUCES THE PLASMA CONCENTRATION OF THE DRUG, HENCE DECREASES ITS EFFICACY
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
ALISKIREN PLASMA CONCENTRATION IS REDUCED UP TO 50%
|
CO-ADMINISTRATION MAY INCREASE C MAX & AUC LEVELS OF ALISKIREN BY ABOUT 50%
|
ALISKIREN PLASMA CONCENTRATION IS REDUCED UP TO 50%
|
ALISKIREN PLASMA CONCENTRATION IS REDUCED UP TO 50%
|